Emcure Pharma delivered a strong performance in Q3, posting healthy growth across key financial metrics and highlighting steady execution despite a competitive pharma environment.
The company’s net profit surged 50% year-on-year to ₹230.5 crore, compared with ₹154 crore in the same quarter last year. This sharp jump reflects improved operating leverage and better cost efficiencies during the quarter.
On the topline front, revenue rose 20.4% YoY to ₹2,363 crore, up from ₹1,962 crore, supported by steady momentum across core therapeutic segments and continued traction in domestic as well as select international markets.
Operating performance also remained robust. EBITDA climbed 39% YoY to ₹493 crore, compared with ₹355 crore a year ago, while EBITDA margins expanded to 20.8% from 18%, indicating stronger profitability and disciplined expense management.
At the market level, Emcure Pharma shares were trading at ₹1,537.00, up ₹30.80 or 2.04%, reflecting a positive investor response following the strong Q3 performance.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.